Aier Eye Hospital Investment Quality Review (300015.SZ)

Data timestamp: 2026-08-03 22:13 UTC
Quality score: 80/100
Valuation position: current price/base FV 1.44
Final signal: WATCHLIST

Core Conclusion

Aier Eye Hospital remains on the watchlist, but valuation is too full. Current price of CNY9.06 is 1.44x base FV of CNY6.30 and 2.50x conservative FV of CNY3.62. The business quality is acceptable; the price is not.

Business Breakdown

Five-year revenue CAGR is 17.2%, with latest-year revenue of CNY22.35bn. The hospital network and specialty-care model support growth, but policy risk, expansion quality, and evidence depth must be monitored carefully.

Business Quality

The 80/100 score reflects growth and solid cash generation. Latest-year FCF was CNY3.88bn. Five-year average ROE was 15.0% and average ROIC was 12.4%. The score does not justify paying materially above base FV.

Financial Audit

Fiscal 2025 revenue was CNY22.35bn, net profit CNY3.24bn, operating cash flow CNY5.97bn, capex CNY2.09bn, and FCF CNY3.88bn. Five-year FCF/net income was 1.14 and OCF/net income was 1.69. Latest net debt was CNY1.92bn.

Valuation

The conservative case uses CNY3.88bn normalized FCF, 2.0% growth, and 9.2x, giving CNY3.62 per share. The base case uses 4.0% growth and 15.6x, giving CNY6.30. The optimistic case uses 5.0% growth and 20.0x, giving CNY8.14. Current price exceeds even the optimistic case.

Buy And Tracking Discipline

The action is watch. A buy requires price/base FV below 0.70, quality above 75, repeatable FCF, and evidence that store expansion, margins, and policy conditions remain favorable.

Risk Review

Risks include medical-service policy changes, acquisition or expansion missteps, doctor retention, utilization weakness, receivables, and leverage. Weak FCF conversion or rising net debt would require a lower FV.

Data Sources

The memo relies on public market and financial data, company filings or investor-relations materials, ChinaBond yield data, and public FX data where applicable. This is research only, not personalized investment advice.